Evenamide
Investigational antipsychotic drug
- None
- 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide
- 1092977-61-1
Y
- 25105689
- 44208827
- ON5S6N53JS
- Interactive image
- CCCCOc1cccc(CCNCC(=O)N(C)C)c1
InChI
- InChI=1S/C16H26N2O2/c1-4-5-11-20-15-8-6-7-14(12-15)9-10-17-13-16(19)18(2)3/h6-8,12,17H,4-5,9-11,13H2,1-3H3
- Key:GRHBODILPPXVKN-UHFFFAOYSA-N
Evenamide (INNTooltip International Nonproprietary Name) (developmental code names NW-3509, NW-3509A) is a selective voltage-gated sodium channel blocker, including (and not limited to) subtypes Nav1.3, Nav1.7, and Nav1.8, which is described as an antipsychotic and is under development by Newron Pharmaceuticals as an add-on therapy for the treatment of schizophrenia.[1][2][3][4] The drug has shown efficacy in animal models of psychosis, mania, depression, and aggression.[3] It has completed phase I clinical trials, and phase II clinical trials will be commenced in the third quarter of 2015.[5]
In a randomized study with treatment-resistant schizophrenia patients, evenamide was added to the treatment regimen, with the psychological assessors being blinded to whether evenamide was taken. 70% of the participants reported a significant lowering of their impairments; and in 25%, schizophrenia went in full remission. A full double-blind phase III study with treatment-resistant schizophrenia patients is in preparation as of January 2023.[6]
See also
References
- ^ "Drug Development in Schizophrenia: Summary and Table". Pharmaceutical Medicine. 28 (5): 265–271. 2014. doi:10.1007/s40290-014-0070-6. ISSN 1178-2595. S2CID 8513976.
- ^ Progress in Medicinal Chemistry. Elsevier. 6 October 2010. pp. 81–. ISBN 978-0-12-381293-3.
- ^ a b Gupta SP (21 June 2011). Ion Channels and Their Inhibitors. Springer Science & Business Media. pp. 102–. ISBN 978-3-642-19922-6.
- ^ Zuliani V, Amori L, Rivara M (2011). "Advances in Design and Development of Sodium Channel Blockers". Ion Channels and Their Inhibitors. pp. 79–115. doi:10.1007/978-3-642-19922-6_4. ISBN 978-3-642-19921-9.
- ^ "Newron raised new funds to continue the development of Neurological therapies". Labiotech. 5 February 2015. Archived from the original on 4 March 2016.
- ^ "Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)". Newron Pharmaceuticals. 2024-01-04. Retrieved 2024-01-04.
External links
- NW-3509 - Newron Pharmaceuticals Archived 2015-05-30 at the Wayback Machine
- NW-3509 - AdisInsight
- v
- t
- e
- Butyrophenones: Benperidol
- Bromperidol
- Droperidol
- Haloperidol#
- Moperone
- Pipamperone
- Spiperone
- Timiperone
- Trifluperidol
- Phenothiazines: Acepromazine
- Acetophenazine
- Butaperazine
- Carphenazine (carfenazine)‡
- Chlorpromazine
- Cyamemazine
- Dixyrazine
- Fluphenazine
- Levomepromazine (methotrimeprazine)
- Mesoridazine
- Perazine
- Periciazine
- Perphenazine
- Piperacetazine
- Pipotiazine
- Prochlorperazine
- Promazine
- Sulforidazine
- Thiopropazate
- Thioproperazine
- Thioridazine
- Trifluoperazine
- Triflupromazine
- Others/unknown: Azacyclonol
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
